Prediction of Amyloid‐Beta PET Status with a Combination of Digital Clock and Recall, Digital Trail Making Test‐Part B, and Blood‐Based Biomarkers

Abstract

Background: Early identification of patients who are likely to have abnormal brain amyloid‐beta (Aβ) levels is crucial for identifying patients with Alzheimer's disease (AD) and prioritizing suitable candidates for disease‐modifying treatments (DMTs).